Innate Pharma (IPHA) Long-Term Investments (2017 - 2025)

Innate Pharma (IPHA) has reported Long-Term Investments for 9 consecutive years, with $11.9 million the latest figure, recorded in Q4 2025.

• Quarterly Long-Term Investments rose 1.69% year-over-year to $11.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $11.9 million (up 1.69% YoY) and the FY2025 annual result came in at $11.9 million, up 1.69% from the prior year.
• Long-Term Investments advanced to $11.9 million in Q4 2025 per IPHA's latest filing, from $11.8 million in the prior quarter.
• Over the last five years, Long-Term Investments for IPHA reached as high as $45.6 million in Q2 2021 and fell as low as $11.1 million in Q4 2023.
• A 5-year average of $27.0 million and a median of $25.8 million in 2022 frame the typical range for Long-Term Investments.
• Annual changes were most pronounced in 2021 — Long-Term Investments plunged 99.88% — and 2024, when it rose 4.95%.
• Year by year, Long-Term Investments stood at $45.4 million in 2021, then fell by 11.93% to $40.0 million in 2022, then slumped by 72.11% to $11.1 million in 2023, then climbed by 4.95% to $11.7 million in 2024, then climbed by 1.69% to $11.9 million in 2025.
• According to Business Quant data, Long-Term Investments over the past three periods registered $11.9 million, $11.8 million, and $11.7 million for Q4 2025, Q2 2025, and Q4 2024 respectively.